Dr Luca Benatti is the Chief Executive Officer and member of the Board since June 2012. He has over 25 years' experience in Pharma and Biotech. He was the Co-founder and CEO of Newron Pharmaceuticals (NWRN, Swiss Stock Exchange). Under his guidance, Newron developed a pipeline of innovative therapies including Xadago, approved worldwide for the treatment of Parkinson's disease. He is an independent Board member at Intercept Pharmaceuticals (ICPT, Nasdaq), Newron Pharmaceuticals, Metis Precision Medicine, Chairman of the Italian Angels for Biotech, Member of the Strategic Advisory Board of Zambon, Member of the Advisory Board of the Sofinnova-Telethon Fund. He has authored several scientific publications and holds numerous patents.